Literature DB >> 29299693

Picosecond 532-nm neodymium-doped yttrium aluminum garnet laser-a promising modality for the management of verrucous epidermal nevi.

Assi Levi1,2, Dan Ben Amitai3,4, Daniel Mimouni3,4, Yael A Leshem3,4, Ofir Arzi4,5, Moshe Lapidoth3,4.   

Abstract

The verrucous epidermal nevus (VEN) is the most common type of epidermal nevi. As lesions can be disfiguring, treatment is often sought. Many therapeutic approaches have been reported, with variable efficacy and safety. Picosecond (PS) lasers are novel laser devices designated to target small chromophores. A side effect of these lasers is blistering due to epidermal-dermal separation. We aimed to harness this side effect of the PS lasers to treat patients with VEN. The purpose of this study was to report our experience treating VEN using a PS 532-nm laser. We present a retrospective case series of six patients with large VEN who were treated using a PS 532-nm laser (2-6 treatments, 8-10 weeks apart). Response in clinical photographs was assessed by two independent dermatologists and graded on a scale of 0 (exacerbation) to 4 (76-100% improvement). Patient satisfaction was recorded on a scale of 1-5. All patients demonstrated significant improvement. Average improvement was 3.7 on the quartile scale of improvement. Patient satisfaction rate averaged 4.7. The PS 532-nm laser is a promising novel modality for the treatment of large VEN.

Entities:  

Keywords:  Dermal-epidermal separation; Epidermal nevus; Esthetic improvement; Laser treatment; Picosecond 532-nm laser; Verrucous epidermal nevus

Mesh:

Year:  2018        PMID: 29299693     DOI: 10.1007/s10103-017-2427-z

Source DB:  PubMed          Journal:  Lasers Med Sci        ISSN: 0268-8921            Impact factor:   3.161


  19 in total

1.  Topical tretinoin and 5-fluorouracil in the treatment of linear verrucous epidermal nevus.

Authors:  J J Kim; M W Chang; T Shwayder
Journal:  J Am Acad Dermatol       Date:  2000-07       Impact factor: 11.527

Review 2.  Full-thickness surgical excision for the treatment of inflammatory linear verrucous epidermal nevus.

Authors:  B J Lee; A J Mancini; J Renucci; A S Paller; B S Bauer
Journal:  Ann Plast Surg       Date:  2001-09       Impact factor: 1.539

3.  Successful treatment with trichloroacetic acid peeling for inflammatory linear verrucous epidermal nevus.

Authors:  Seiko Toyozawa; Yuki Yamamoto; Chikako Kaminaka; Akiko Kishioka; Nozomi Yonei; Fukumi Furukawa
Journal:  J Dermatol       Date:  2010-04       Impact factor: 4.005

4.  Novel postzygotic KRAS mutation in a Japanese case of epidermal nevus syndrome presenting with two distinct clinical features, keratinocytic epidermal nevi and sebaceous nevi.

Authors:  Satomi Igawa; Masaru Honma; Masako Minami-Hori; Etsushi Tsuchida; Hajime Iizuka; Akemi Ishida-Yamamoto
Journal:  J Dermatol       Date:  2015-10-26       Impact factor: 4.005

Review 5.  Epidermal nevus syndromes.

Authors:  Jeffrey L Sugarman
Journal:  Semin Cutan Med Surg       Date:  2007-12

6.  Successful treatment of inflammatory linear verrucous epidermal nevus with tacrolimus and fluocinonide.

Authors:  Diya F Mutasim
Journal:  J Cutan Med Surg       Date:  2006 Jan-Feb       Impact factor: 2.092

7.  Laser therapy of verrucous epidermal naevi.

Authors:  U Hohenleutner; M Landthaler
Journal:  Clin Exp Dermatol       Date:  1993-03       Impact factor: 3.470

8.  CO2 laser treatment of epidermal nevi: long-term success.

Authors:  Sarah Boyce; Tina S Alster
Journal:  Dermatol Surg       Date:  2002-07       Impact factor: 3.398

9.  Analysis of mutations in the PIK3CA and FGFR3 genes in verrucous epidermal nevus.

Authors:  Ludmilla Queirós Miranda; Tainá Scalfoni Fracaroli; João Carlos Macedo Fonseca; Elisa Fontenelle; Raphael Pedro Machado Curvo; Luís Cristóvão Porto; Roberto Souto
Journal:  An Bras Dermatol       Date:  2013 Nov-Dec       Impact factor: 1.896

Review 10.  Mosaic Neurocutaneous Disorders and Their Causes.

Authors:  Martino Ruggieri; Andrea D Praticò
Journal:  Semin Pediatr Neurol       Date:  2015-11-12       Impact factor: 1.636

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.